InVivoSIM anti-human TROP-2(Sacituzumab Biosimilar)

InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar) clone: Sacituzumab (Catalog #SIM0051)

产品中文名称：InVivoSIM 抗人TROP-2（Sacituzumab 生物仿制药）抗体，克隆：Sacituzumab（目录号 #SIM0051）

（产品示例图）

Key features:

▲ Sacituzumab is a humanized IgG1κ against human trophoblastic cell surface antigen 2 (TROP-2).

▲ TROP-2 is a cell surface receptor, and its ligands include claudin-1, claudin-7, cyclin D1, and IGF-1.

▲ TROP2 is an upcoming tumor antigen that is expressed in glioblastoma, pancreatic carcinoma, and all breast cancer subtypes. TROP-2 is a cellular marker of trophoblastic stem cells.

▲ TROP2 transduces calcium signals and drives tumor proliferation, invasion, and metastasis.

▲ The tumor cell-specific expression of TROP-2 makes it an ideal target for cancer immunotherapy.

▲ Sacituzumab is used for making antibodydrug conjugates (ADC) and also to eradicate cancer cells.

Application: in vitro functional assays, in vivo functional assays, Antibody-drug conjugate synthesis, ELISA, Western blot, Flow cytometry

cytometry Research Area: Tumor Antigens, Cancer Biology

Related targets: EGFR, EPCAM (CD326), HER2/erbB2, PSMA, EphA2, CEACAM

主要特点：

▲ Sacituzumab 是一种针对人滋养细胞表 面抗原 2（TROP-2）的重组人源化 IgG1κ 抗体。

▲ TROP-2 是一种细胞表面受体，其配体 包括 claudin-1、claudin-7、cyclin D1 和 IGF-1。

▲ TROP-2 是新兴的肿瘤抗原，表达于胶 质母细胞瘤、胰腺癌以及所有乳腺癌亚 型中。TROP-2 是滋养细胞干细胞的细 胞标志物。

▲ TROP-2 传导钙信号，并驱动肿瘤的增 殖、侵袭和转移。

▲ TROP-2 在肿瘤细胞中的特异性表达使 其成为癌症免疫疗法的理想靶点。

▲ Sacituzumab 用于抗体药物偶联物 （ADC）的合成，同时也用于消除癌细 胞。

应用：体外功能实验、体内功能实验、抗体药物偶 联物合成、ELISA、Western blot、流式细胞术

研究领域：肿瘤抗原、癌症生物学

相关靶点：EGFR、EPCAM（CD326）、HER2/erbB2、 PSMA、EphA2、CEACAM 

更多详情请联系 BioXCell 中国授权一级代理-欣博盛生物科技